


AT A GLANCE


Key figures – 3rd quarter 2010

EUR million	Pharma- ceuticals	Chemicals	Corporate and Other	Total	Change in %
Total revenues	1,518.4	919.4	–	2,437.8	25.0
Gross margin	1,286.0	532.1	–	1,818.2	27.3
Research and development	–285.1	–63.5	–	–348.6	4.7
Operating result	225.7	161.8	–24.1	363.5	63.6
Exceptional items	–	–	–	–	–
Earnings before interest and tax (EBIT)	225.7	161.8	–24.1	363.5	63.6
EBIT before depreciation and amortization (EBITDA)	423.4	301.2	–22.9	701.7	54.0
Return on sales in % (ROS: operating result/total revenues)	14.9	17.6	–	14.9	
Free cash flow	418.1	–4,673.0	–127.9	–4,382.9	–
Underlying free cash flow	418.1	267.3	–124.6	560.7	30.6
Underlying free cash flow on revenues (FCR) in %	27.5	29.1	–	23.0	

Total revenues by quarter



Operating result by quarter



HIGHLIGHTS – 3rd QUARTER 2010

- Total revenues increase 25% to a record EUR 2.4 billion
- Profit after tax rises 45% to EUR 215 million
- Rebif® sales +6.8% to EUR 407 million; Erbitux® sales +17% to EUR 207 million
- Liquid Crystals revenues up 21% to EUR 255 million
- 2010 Group core operating result guidance lifted to 58%
- Millipore acquisition completed on July 14, figures consolidated in Q3, integration underway